Table 2.
Solid malignancies detected in 13 patients after completion of WGET: treatment assignment, disease severity of WG and immunosuppressant drug use.
| Case | Arm | Disease extent |
Age1/ Gender |
Type of cancer | Time to cancer after enrollment/ closeout (m) |
Previous cancer/ time before enrollment |
CYC USE (grams)
|
Other drug use (type)
|
Vital status |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before trial |
During trial |
After trial |
Before trial |
During trial |
After trial |
||||||||
| 1 | EG | Limited | 29/F | Melanoma | 61/27 | no | 24 | 20 | no | MTX | MTX AZA |
Alive | |
| 2 | Limited | 36/M | Squamous cell (tonsillar) carcinoma | 52/14 | no | 183 | no | no | MTX | MTX AZA |
Alive | ||
| 3 | Limited | 71/M | Squamous (transitional) cell, metastatic | 56/39 | Bladder Ca., 8 years | 264 | no | no | MTX | MTX | Dead | ||
| 4 | Limited | 70/M | Prostate cancer | 31/4 | No | no | no | yes | MTX | MTX AZA |
Alive | ||
| 5 | Severe | 56/M | Prostate cancer | 50/36 | No | no | 50 | yes | AZA | MTX | Alive | ||
| 6 | Severe | 57/M | Melanoma | 62/30 | No | 84 | 7 | no | AZA | AZA | Alive | ||
| 7 | Severe | 66/F | Cholangiocarcinoma | 38/21 | Breast ca, 12 years | 48 | 7 | no | AZA | MTX | MTX | Dead | |
| 8 | Severe | 63/M | Small bowel | 78/45 | Squamous skin ca, >5 years | 105 | no | no | AZA | MTX | MTX AZA |
Alive | |
|
| |||||||||||||
| 9 | PG | Limited | 62/M | Bladder carcinoma | 66/34 | No | 144 | no | no | AZA Cyclo |
MTX | MTX | Alive |
| 10 | Severe | 42/M | Renal cell carcinoma | 49/16 | No | 1 | 24 | no | AZA | Dead | |||
| 11 | Severe | 57/M | Colon cancer | 35/3 | No | 2.5 | 11.9 | no | MTX AZA |
Dead | |||
| 12 | Severe | 61/M | Prostate cancer | 34/5 | Melanoma, 15 years | 64 | 21 | no | Alive | ||||
| 13 | Severe | 71/F | Cholangiocarcinoma | 59/26 | No | 40 | 11 | no | MTX | MTX AZA |
Alive | ||
1
Age at enrollment in WGET.
EG: Etanercept group, PG: Placebo group
CYC: Cyclophosphamide, MTX: Methotrexate, AZA: Azathioprine, Cyclo: Cyclosporine